Strata Critical Medical, Inc. (SRTA)
NASDAQ: SRTA · Real-Time Price · USD
4.750
-0.140 (-2.86%)
At close: Mar 5, 2026, 4:00 PM EST
4.730
-0.020 (-0.42%)
After-hours: Mar 5, 2026, 6:02 PM EST
Strata Critical Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Strata Critical Medical stock have an average target of 7.63, with a low estimate of 7.25 and a high estimate of 8.00. The average target predicts an increase of 60.63% from the current stock price of 4.75.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 2, 2025.
Analyst Ratings
The average analyst rating for Strata Critical Medical stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|
| Strong Buy | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +68.42% | Dec 2, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $6.5 → $7.25 | Strong Buy | Maintains | $6.5 → $7.25 | +52.63% | Sep 17, 2025 |
Financial Forecast
Revenue This Year
271.83M
from 197.14M
Increased by 37.89%
Revenue Next Year
310.79M
from 271.83M
Increased by 14.33%
EPS This Year
-0.06
from 0.50
EPS Next Year
-0.03
from -0.06
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 283.5M | 319.9M |
| Avg | 271.8M | 310.8M |
| Low | 257.7M | 298.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 43.8% | 17.7% |
| Avg | 37.9% | 14.3% |
| Low | 30.7% | 9.9% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 0.08 | -0.03 |
| Avg | -0.06 | -0.03 |
| Low | -0.19 | -0.03 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | -83.3% | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.